RecruitingPhase 1Phase 2NCT07602842

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

A Phase 1/2 Open-label Study of IDP-001 in Advanced or Metastatic Squamous Cell Lung Cancer and Other Solid Tumors

Sponsor

InduPro, Inc.

Enrollment

132 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Metastatic Solid Tumor Head and Neck Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma Squamous Cell Carcinoma Non-squamous Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Anus Squamous Cell Carcinoma of the Cervix Squamous Cell Carcinoma of the Esophagus

Summary

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IDP-001 for people with advanced solid tumor, cutaneous squamous cell carcinoma, and other related conditions. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.